hydralazine has been researched along with Ventricular Dysfunction, Left in 22 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the effect of acute heart failure and the subsequent administration of hydralazine, enalaprilat, and nitroglycerin on the splanchnic venous pressure-volume relation in intact dogs." | 7.69 | Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. ( Manyari, DE; Scott-Douglas, N; Smiseth, OA; Smith, ER; Tyberg, JV; Wang, SY, 1995) |
| " Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature." | 5.35 | Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. ( Jacob, RG; Thadani, U, 2008) |
| "The purpose of this study was to evaluate the influence of the guanine nucleotide-binding proteins (G-proteins), beta-3 subunit (GNB3) genotype on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in A-HeFT (African American Heart Failure Trial)." | 5.19 | G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. ( Cohn, JN; Feldman, AM; Hanley-Yanez, K; McNamara, DM; Tam, SW; Taylor, AL; Worcel, M; Yancy, CW, 2014) |
| "Hydralazine and isosorbide dinitrate combination (H+ISDN), angiotensin-converting enzyme inhibitors, and beta-blockers have improved outcomes in heart failure (HF)." | 5.10 | African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. ( Cohn, JN; Ferdinand, K; Franciosa, JA; Loscalzo, J; Ofili, E; Olukotun, A; Taylor, AL; Worcel, M; Yancy, CW; Ziesche, S, 2002) |
| " Digoxin has not been shown to affect the natural history of heart failure and should be reserved for patients who remain symptomatic after treatment with ACE inhibitors and diuretics." | 4.79 | Management of heart failure. I. Pharmacologic treatment. ( Baker, DW; Bottorff, M; Konstam, MA; Pitt, B, 1994) |
| "Although amlodipine, a long-acting L-type calcium channel blocker, reportedly prevents left ventricular remodeling and dysfunction after myocardial infarction, the mechanism responsible is not yet well understood." | 3.74 | Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. ( Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007) |
| " We assessed the effect of acute heart failure and the subsequent administration of hydralazine, enalaprilat, and nitroglycerin on the splanchnic venous pressure-volume relation in intact dogs." | 3.69 | Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. ( Manyari, DE; Scott-Douglas, N; Smiseth, OA; Smith, ER; Tyberg, JV; Wang, SY, 1995) |
| " To select the most appropriate drug therapy for patients with heart failure, clinicians should consider results from clinical trials in specific patient populations, adverse-event profiles, tolerability, cost, and dosing regimens." | 2.44 | Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers. ( Norgard, NB; Stark, JE, 2008) |
| " Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature." | 1.35 | Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. ( Jacob, RG; Thadani, U, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McNamara, DM | 1 |
| Taylor, AL | 2 |
| Tam, SW | 1 |
| Worcel, M | 2 |
| Yancy, CW | 2 |
| Hanley-Yanez, K | 1 |
| Cohn, JN | 4 |
| Feldman, AM | 1 |
| Norgard, NB | 1 |
| Stark, JE | 1 |
| Thadani, U | 1 |
| Jacob, RG | 1 |
| Jacoby, D | 1 |
| Albajrami, O | 1 |
| Bellumkonda, L | 1 |
| Westermann, D | 1 |
| Becher, PM | 1 |
| Lindner, D | 1 |
| Savvatis, K | 1 |
| Xia, Y | 1 |
| Fröhlich, M | 1 |
| Hoffmann, S | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Franciosa, JA | 1 |
| Ziesche, S | 1 |
| Olukotun, A | 1 |
| Ofili, E | 1 |
| Ferdinand, K | 1 |
| Loscalzo, J | 1 |
| Ahmed, A | 1 |
| Levine, TB | 1 |
| Levine, AB | 1 |
| Bolenbaugh, J | 1 |
| Green, PR | 1 |
| Wallace, TW | 1 |
| Drazner, MH | 1 |
| Matthews, GE | 1 |
| Shi, YX | 1 |
| Chen, Y | 1 |
| Zhu, YZ | 1 |
| Huang, GY | 1 |
| Moore, PK | 1 |
| Huang, SH | 1 |
| Yao, T | 1 |
| Zhu, YC | 1 |
| Ogino, A | 1 |
| Takemura, G | 1 |
| Kanamori, H | 1 |
| Okada, H | 1 |
| Maruyama, R | 1 |
| Miyata, S | 1 |
| Esaki, M | 1 |
| Nakagawa, M | 1 |
| Aoyama, T | 1 |
| Ushikoshi, H | 1 |
| Kawasaki, M | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Wang, SY | 1 |
| Manyari, DE | 1 |
| Scott-Douglas, N | 1 |
| Smiseth, OA | 1 |
| Smith, ER | 1 |
| Tyberg, JV | 1 |
| Baker, DW | 1 |
| Konstam, MA | 1 |
| Bottorff, M | 1 |
| Pitt, B | 1 |
| Carson, P | 1 |
| Johnson, G | 1 |
| Fletcher, R | 1 |
| Cohn, J | 1 |
| Norton, GR | 1 |
| Tsotetsi, J | 1 |
| Trifunovic, B | 1 |
| Hartford, C | 1 |
| Candy, GP | 1 |
| Woodiwiss, AJ | 1 |
| Adams, KF | 1 |
| Ellis, ML | 1 |
| Williamson, KM | 1 |
| Patterson, JH | 1 |
| Adigun, AQ | 1 |
| Ajayi, OE | 1 |
| Sofowora, GG | 1 |
| Ajayi, AA | 1 |
| Knowles, JW | 1 |
| Esposito, G | 1 |
| Mao, L | 1 |
| Hagaman, JR | 1 |
| Fox, JE | 1 |
| Smithies, O | 1 |
| Rockman, HA | 1 |
| Maeda, N | 1 |
| Aronow, WS | 1 |
6 reviews available for hydralazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Combinations; Heart Failure; Humans; Hydralazine; Isos | 2008 |
The impact of race on response to RAAS inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Clinical Trials as Topic; Diuretics, Osmotic | 2005 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Symp | 1995 |
Management of heart failure. I. Pharmacologic treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Decision Support Techniques; Digoxin; Diuretics; Heart Fai | 1994 |
Left ventricle and arteries: structure, function, hormones, and disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine Vasopressin; Dr | 2001 |
Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2001 |
5 trials available for hydralazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
Topics: Analysis of Variance; Black or African American; Disease-Free Survival; Drug Combinations; Female; G | 2014 |
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Topics: Adolescent; Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Female; Heart Failure | 2002 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Symp | 1995 |
Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; He | 1996 |
Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate.
Topics: Adult; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Hydralazine; H | 1998 |
12 other studies available for hydralazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interactions; D | 2008 |
Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynch | 2011 |
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Typ | 2012 |
American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echoca | 2003 |
Reversal of heart failure remodeling: is it maintained?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomyopathies; Echocardiography; Female | 2003 |
BiDil: primary care physicians first and cardiologist when?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Ca | 2007 |
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cardiomegaly; Cardiotonic | 2007 |
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; C | 2007 |
Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin.
Topics: Animals; Dogs; Enalaprilat; Heart Failure; Hydralazine; Mesenteric Veins; Nitroglycerin; Plethysmogr | 1995 |
Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Body Weight; Captopril; Collagen; Cross-Linking Reagents; Diastole | 1997 |
The AHCPR clinical practice guideline for heart failure revisited.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Calcium Chann | 1997 |
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Enalapril; Furosemide; Guanylate Cyc | 2001 |